Home Companies Catalysts Deep Dives

Myelodysplastic syndrome

MDS · Oncology · 3 drugs · 2 indications

Competitive Landscape (3 drugs)
DrugCompanyMechanismModalityRouteStage
VenclextaABBV, ROG.SWBCL-2 inhibitorSmall moleculePOAPPROVED
RyteloSOBITelomerase inhibitorOligonucleotideIVAPPROVED
Reblozyl—Activin receptor ligand trap (erythroid maturation)Fusion proteinSCAPPROVED
Indications (2)
Lower-risk MDS, transfusion-dependent (non-del(5q))
Rytelo APPROVEDReblozyl APPROVED
Higher risk MDS
Venclexta PHASE3
Upcoming Catalysts
Venclexta - HR-MDS - FDA ApprovalREGULATORY
ABBV2026
Rytelo - Lower-risk MDS - EU Country-by-Country LaunchCOMMERCIAL
SOBIThroughout 2026
Data from Supabase · Updated 2026-03-24